The United States is a key market for liquid biopsy technologies, supported by strong investments in cancer research, widespread adoption of precision medicine, and advanced molecular diagnostic capabilities. The growing focus on early cancer detection, personalized treatment strategies, and non-invasive diagnostic methods continues to drive demand for liquid biopsy solutions across healthcare...